Eli Lilly's bid for Kelonia Therapeutics under review in Australia
MLex Summary: Eli Lilly's bid to wholly acquire Kelonia Therapeutics is under review by Australia's competition watchdog. In a Monday statement, the Australian Competition & Consumer Commission said that Eli Lilly, headquartered in...To view the full article, register now.
Already a subscriber? Click here to view full article